Document
type: Class

Academic Article
type: Class

http://irises.unipv.it/resource/item/528022
type: Document
type: Information Content Entity
type: Academic Article
most specific type: Academic Article
type: Thing
language: Inglese
label: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
type: Generically Dependent Continuant
type: Article
related by: 215115360
type: Continuant
type: Entity

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

Article
type: Class

215115360
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: http://irises.unipv.it/resource/item/528022

individual
rights: termsOfUse
date: 2026-08-31T22:36:59
publisher: http://irises.unipv.it/resource/item/528022
type: Document
label: RDF description of Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy - http://irises.unipv.it/resource/item/528022

Inglese
type: Language

Information Content Entity
type: Class